Original Publication Date: 1 July, 2016
Publication / Source: Personalized Medicine
Authors: Jella-Andrea Abraham, Kristina Yeghiazaryan & Olga Golubnitschaja
Hepatocellular carcinoma (HCC) is a global health problem, with more than half a million new cases diagnosed annually and mortality rates at similar level. The majority of HCC is diagnosed at intermediate–advanced stages being, therefore, an issue for palliative rather than curative care. Selective internal radiation therapy (SIRT) is one of the best appropriate palliative treatment modalities in HCC management. Although delivering satisfactory results, SIRT application comes along with frequent complications and tumor recurrence.